ABIVAX Société Anonyme (0RA9.L)

EUR 5.15

(-2.65%)

Long Term Debt Summary of ABIVAX Société Anonyme

ABIVAX Société Anonyme's latest annual long term debt in 2023 was 44.69 Million EUR , up 22.21% from previous year.
ABIVAX Société Anonyme's latest quarterly long term debt in 2024 Q2 was 73.57 Million EUR , down 0.0% from previous quarter.
ABIVAX Société Anonyme reported annual long term debt of 36.57 Million EUR in 2022, down -15.21% from previous year.
ABIVAX Société Anonyme reported annual long term debt of 43.13 Million EUR in 2021, up 51.64% from previous year.
ABIVAX Société Anonyme reported quarterly long term debt of 44.69 Million EUR for 2023 Q4, down 0.0% from previous quarter.
ABIVAX Société Anonyme reported quarterly long term debt of 44.69 Million EUR for 2023 FY, up 22.21% from previous quarter.

Annual Long Term Debt Chart of ABIVAX Société Anonyme (2023 - 2013)

Historical Annual Long Term Debt of ABIVAX Société Anonyme (2023 - 2013)

Year	Long Term Debt	Long Term Debt Growth
2023	44.69 Million EUR	22.21%
2022	36.57 Million EUR	-15.21%
2021	43.13 Million EUR	51.64%
2020	28.44 Million EUR	63.65%
2019	17.38 Million EUR	59.47%
2018	10.9 Million EUR	11747.83%
2017	92 Thousand EUR	-70.89%
2016	316 Thousand EUR	-27.36%
2015	435 Thousand EUR	-79.18%
2014	2.08 Million EUR	-9.95%
2013	2.32 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	73.57 Million EUR	0.0%
2023 Q4	44.69 Million EUR	0.0%
2023 FY	44.69 Million EUR	22.21%
2023 Q2	28.23 Million EUR	0.0%
2022 Q2	38.19 Million EUR	0.0%
2022 Q4	36.57 Million EUR	0.0%
2022 FY	36.57 Million EUR	-15.21%
2021 FY	43.13 Million EUR	51.64%
2021 Q2	23.84 Million EUR	0.0%
2021 Q4	43.13 Million EUR	0.0%
2020 FY	28.44 Million EUR	63.65%
2020 Q2	20.19 Million EUR	0.0%
2020 Q4	28.44 Million EUR	0.0%
2019 Q4	17.38 Million EUR	0.0%
2019 FY	17.38 Million EUR	59.47%
2019 Q2	19.48 Million EUR	0.0%
2018 Q2	- EUR	0.0%
2018 FY	10.9 Million EUR	11747.83%
2018 Q4	10.9 Million EUR	0.0%
2017 Q4	262 Thousand EUR	0.0%
2017 FY	92 Thousand EUR	-70.89%
2017 Q2	76 Thousand EUR	0.0%
2016 Q4	316 Thousand EUR	0.0%
2016 Q2	46 Thousand EUR	0.0%
2016 FY	316 Thousand EUR	-27.36%
2015 Q4	435 Thousand EUR	0.0%
2015 FY	435 Thousand EUR	-79.18%
2015 Q2	255 Thousand EUR	0.0%
2014 Q4	2.08 Million EUR	99922.98%
2014 Q3	2089.00 EUR	0.0%
2014 FY	2.08 Million EUR	-9.95%
2014 Q1	- EUR	0.0%
2013 FY	2.32 Million EUR	0.0%

Peer Long Term Debt Comparison of ABIVAX Société Anonyme

Name	Long Term Debt	Long Term Debt Difference
Boiron SA	6.64 Million EUR	-572.641%
Laboratorios Farmaceuticos Rovi, S.A.	38.57 Million EUR	-15.87%
Vetoquinol SA	9.66 Million EUR	-362.558%
Valneva SE	132.76 Million EUR	66.335%
AB Science S.A.	16.98 Million EUR	-163.109%
Nanobiotix S.A.	41.66 Million EUR	-7.29%
PHAXIAM Therapeutics S.A.	7.03 Million EUR	-535.804%
Vivoryon Therapeutics N.V.	- EUR	-Infinity%
BioSenic S.A.	15.57 Million EUR	-187.016%
Formycon AG	7.81 Million EUR	-471.939%